Insa E Emrich1, Adam M Zawada2, Jens Martens-Lobenhoffer3, Danilo Fliser2, Stefan Wagenpfeil4, Gunnar H Heine2, Stefanie M Bode-Böger3. 1. Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Center, Homburg, Germany. insa.emrich@uks.eu. 2. Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Center, Homburg, Germany. 3. Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany. 4. Institute for Medical Biometry, Epidemiology and Medical Informatics, Saarland University Faculty of Medicine, Homburg, Germany.
Abstract
BACKGROUND: Chronic kidney disease (CKD) is associated with increased risk of renal and cardiovascular events. It has been claimed that endogenous methylarginines, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), are contributing factors. However, earlier studies were partly contradictory and mainly focused on prevalent dialysis patients. Moreover, the potential contribution of degradation products, such as acetylated ADMA and SDMA (AcADMA and AcSDMA) and other methylarginines including L-NG-monomethylarginine (LNMMA) remains unknown. To better understand their potential pathophysiological contribution to renal and cardiovascular events, we aimed to provide a comprehensive analysis of methylarginines in a cohort of patients with non-dialysis CKD. METHODS: Blood samples of 528 patients with CKD KDIGO G2 to G4 were obtained from the CARE FOR HOMe study. Baseline plasma levels of ADMA, SDMA, AcADMA, AcSDMA, and LNMMA were measured by liquid chromatography-tandem mass spectrometry. All patients were followed annually for CKD progression and for incident atherosclerotic cardiovascular events. RESULTS: During 5.1 ± 2.1 years follow-up, 80 patients displayed CKD progression and 145 patients developed incident atherosclerotic cardiovascular events. In univariate Cox regression analyses, elevated plasma levels of all five metabolites were associated with both CKD progression and atherosclerotic cardiovascular disease. However, adjustment for confounders attenuated the prognostic implications of ADMA, LNMMA, AcADMA and AcSDMA. In contrast, patients in the highest tertile of plasma SDMA remained at highest risk for CKD progression and incident atherosclerotic cardiovascular events in fully adjusted Cox regression analyses. CONCLUSION: Our results underline a potential pathophysiological role of SDMA in CKD progression and atherosclerotic cardiovascular disease among non-dialysis CKD patients. SDMA predicts CKD progression and future atherosclerotic cardiovascular events more consistently than other methylarginines. Future experimental and clinical studies should therefore focus upon SDMA rather than upon ADMA.
BACKGROUND:Chronic kidney disease (CKD) is associated with increased risk of renal and cardiovascular events. It has been claimed that endogenous methylarginines, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), are contributing factors. However, earlier studies were partly contradictory and mainly focused on prevalent dialysis patients. Moreover, the potential contribution of degradation products, such as acetylated ADMA and SDMA (AcADMA and AcSDMA) and other methylarginines including L-NG-monomethylarginine (LNMMA) remains unknown. To better understand their potential pathophysiological contribution to renal and cardiovascular events, we aimed to provide a comprehensive analysis of methylarginines in a cohort of patients with non-dialysis CKD. METHODS: Blood samples of 528 patients with CKD KDIGO G2 to G4 were obtained from the CARE FOR HOMe study. Baseline plasma levels of ADMA, SDMA, AcADMA, AcSDMA, and LNMMA were measured by liquid chromatography-tandem mass spectrometry. All patients were followed annually for CKD progression and for incident atherosclerotic cardiovascular events. RESULTS: During 5.1 ± 2.1 years follow-up, 80 patients displayed CKD progression and 145 patients developed incident atherosclerotic cardiovascular events. In univariate Cox regression analyses, elevated plasma levels of all five metabolites were associated with both CKD progression and atherosclerotic cardiovascular disease. However, adjustment for confounders attenuated the prognostic implications of ADMA, LNMMA, AcADMA and AcSDMA. In contrast, patients in the highest tertile of plasma SDMA remained at highest risk for CKD progression and incident atherosclerotic cardiovascular events in fully adjusted Cox regression analyses. CONCLUSION: Our results underline a potential pathophysiological role of SDMA in CKD progression and atherosclerotic cardiovascular disease among non-dialysis CKD patients. SDMA predicts CKD progression and future atherosclerotic cardiovascular events more consistently than other methylarginines. Future experimental and clinical studies should therefore focus upon SDMA rather than upon ADMA.
Authors: Bob Siegerink; Renke Maas; Carla Y Vossen; Edzard Schwedhelm; Wolfgang Koenig; Rainer Böger; Dietrich Rothenbacher; Hermann Brenner; Lutz P Breitling Journal: Clin Res Cardiol Date: 2012-10-17 Impact factor: 5.460
Authors: Wesley T O'Neal; Jimmy T Efird; Hooman Kamel; Saman Nazarian; Alvaro Alonso; Susan R Heckbert; W T Longstreth; Elsayed Z Soliman Journal: Clin Res Cardiol Date: 2015-03-10 Impact factor: 5.460
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: Peter Willeit; Daniel F Freitag; Jari A Laukkanen; Susmita Chowdhury; Reeta Gobin; Manuel Mayr; Emanuele Di Angelantonio; Rajiv Chowdhury Journal: J Am Heart Assoc Date: 2015-05-28 Impact factor: 5.501
Authors: Hima Sapa; Orlando M Gutiérrez; Michael G Shlipak; Ronit Katz; Joachim H Ix; Mark J Sarnak; Mary Cushman; Eugene P Rhee; Paul L Kimmel; Ramachandran S Vasan; Sarah J Schrauben; Harold I Feldman; Jesse C Seegmiller; Henri Brunengraber; Thomas H Hostetter; Jeffrey R Schelling Journal: Am J Kidney Dis Date: 2022-03-26 Impact factor: 11.072
Authors: André Nanny Vieira Le Sueur; Silvano Salgueiro Geraldes; Alessandra Melchert; Regina Kiomi Takahira; Michael Coyne; Rachel Murphy; Donald Szlosek; Priscylla Tatiana Chalfun Guimarães-Okamoto Journal: J Vet Intern Med Date: 2019-09-12 Impact factor: 3.333